PARIS & TARRYTOWN, N.Y.--(BUSINESS WIRE)--Dec. 22, 2005--Sanofi-aventis (EURONEXT:SAN and NYSE:SNY) and Regeneron Pharmaceuticals, Inc. (Nasdaq:REGN) announced today that they have amended their Vascular Endothelial Growth Factor (VEGF) Trap collaboration agreement to include Japan. The companies will now collaborate on the joint development and commercialization of the VEGF Trap throughout the world in all indications, except for intraocular delivery to the eye. As remuneration for the inclusion of Japan into the VEGF Trap collaboration, Regeneron will receive an upfront payment of $25 million, milestone payments related to potential approvals in Japan, and royalties on sales of the VEGF Trap in Japan. Sanofi-aventis will lead and fund the development of the VEGF Trap in Japan.